Healthcare › Biotechnology
Biogen
- Ticker
- BIIB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
Price data arrives in a later stage, so no price is shown yet.
Latest news
Company newsBIIB
Explain this story: Biogen phase 2 litifilimab data boosts lupus candidate
Long-term phase 2 data for Biogen's litifilimab showed promising results for cutaneous lupus erythematosus. After one year, patients achieved clear skin and reduced disease activity. This data comes from the AMETHYST Phase 2/3 trial, supporting the candidate's potential.
OtherSeeking AlphaSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Long-term phase 2 data for Biogen's litifilimab showed promising results for cutaneous lupus erythematosus. After one year, patients achieved clear skin and reduced disease activity. This data comes from the AMETHYST Phase 2/3 trial, supporting the candidate's potential.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.
Company newsBIIB
Explain this story: Biogen reports 52-week litifilimab data for lupus treatment
Biogen (NASDAQ:BIIB) has announced 52-week results from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE). The data showed improvements in skin disease activity, with 27.2% of initial participants achieving clear or almost clear skin by week 52, and 33.7% of those who switched from placebo to litifilimab also showing significant improvement. The drug was generally well-tolerated, and the Phase 3 study results are anticipated in the first half of 2027, as there are currently no approved targeted therapies for CLE.
OtherInvesting.com India
Company newsBIIB
Explain this story: Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine (NASDAQ: PRME) has received FDA clearance for its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company plans to initiate a global Phase 1/2 clinical trial to assess the safety and efficacy of PM647, which aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene. PM647 is designed to restore functional M-AAT protein levels to address both liver and lung complications of AATD.
OtherBenzingaSector and industry: Healthcare
Company newsBIIB
Explain this story: Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast
Helus Pharma (operating as Cybin Inc.) CEO Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company is advancing HLP003, a Phase 3 novel serotonergic agonist (NSA) with FDA Breakthrough Therapy Designation for major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder. This participation highlights the company's late-stage pipeline for mental health conditions.
OtherStock TitanHealthcare
Elsewhere
These links open other websites. We do not provide price data yet.